Development and Evaluation of Chitosan-Coated PLGA Nanoparticles of Canagliflozin for the Treatment of Hepatic Cancer
1, 1, 2
- 1Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, SAUDI ARABIA.
- 2Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, SAUDI ARABIA.
CORRESPONDENCE
Shadab Md
Department of Pharmaceutics Faculty of Pharmacy, King Abdulaziz University, Jeddah, SAUDI ARABIA.
Received: 18-07-2025; Revised: 24-09-2025; Accepted: 03-11-2025.
Volume 60, Issue 2s (Supplement) · pp. s475-s489 · 2026 · DOI: 10.5530/ijper.20263737
ABSTRACT
Aim: The aim of the study was to develop, optimize and evaluate chitosan-coated Poly (Lactic-Co- Glycolic Acid) (PLGA) Nanoparticles (NPS) of Canagliflozin (CFZ) against the proliferation of liver cancer cells.Materials and Methods: The PLGA NPs and chitosan-coated PLGA NPs containing CFZ was optimized keeping CFZ:PLGA ratios and PVA levels as independent variables and mean Particle Size (PS), Polydispersity Index (PDI), Zeta Potential (ZP), and percent Entrapment Efficiency (EE) as the responses.Results: The optimized CFZ-PLGA-NPs had PS, PDI, ZP, and EE values of 159 nm, 0.149, -36.5 mV, 84.8%, respectively. The concentration of chitosan coating (0.25%) was found to be optimum providing a PS of 277±23 nm, PDI of 0.241±0.011, ZP of 57.2±0.67 mV, and EE of 80.5±1.78%. The electron microscope images, FTIR spectra, and DSC thermograms confirmed the identity of individual components and the amorphous nature of CFZ in the C-CFZ-PLGA-NPs. The in vitro CFZ release from C-CFZ-PLGA-NPs (80.9±1.2%) was significantly higher than that from CFZ dispersion (25.9±1.4%) when studied for 48 h. The cell viability assay demonstrated significant enhancement of cytotoxicity of C-CFZ-PLGA-NPs against HepG2 cells compared to pure CFZ treatments. The C-CFZ-PLGA-NPs were found to be stable when tested for storage stability at 4ºC for 90 days. PS, PDI, and ZP remained stable during the entire study period.Conclusion: C-CFZ-PLGA-NPs can be considered potential candidates for further studies in providing a commercially viable, stable, and effective system for the delivery of CFZ
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Md, S., Alharthi, E. A. A., & Karim, S. (2026). Development and Evaluation of Chitosan-Coated PLGA Nanoparticles of Canagliflozin for the Treatment of Hepatic Cancer. Indian Journal of Pharmaceutical Education and Research, 60(2s), s475-s489. https://doi.org/10.5530/ijper.20263737
Copyright and licence
© 2026 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. CC BY 4.0